FMP
CARGO Therapeutics, Inc. Common Stock
CRGX
NASDAQ
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
4.64 USD
0.035 (0.755%)
CRGX Financial Statements
Year
2024
2023
2022
2021
CF from Operating Activities
-139.74M
-81.16M
-29.07M
-4.94M
Net Income
-167.5M
-98.15M
-40.95M
-5.85M
Depreciation & Amortization
7.07M
3.69M
1.44M
147k
Deferred Income Taxes
0
0
1.22M
0
Stock Based Compensation
17.97M
3.33M
297k
507k
Change in Working Capital
5.77M
2.21M
2.97M
254k
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
-2.1M
757k
2.82M
332k
Other Working Capital
7.87M
1.45M
148k
-78k
Other Non-Cash Items
-3.06M
7.75M
5.96M
469k
CF from Investing Activities
-305.08M
-8.99M
-3.28M
-442k
Investments in Property, Plant & Equipment
-4.45M
-8.28M
-3.28M
-442k
Net Acquisitions
0
0
0
0
Investment Purchases
-608.39M
0
0
0
Sales/Maturities of Investments
304.97M
0
0
0
Other Investing Activites
2.79M
-715k
-558k
0
CF from Financing Activities
103.47M
494.58M
34.19M
5.41M
Debt Repayment
0
3.5M
-28.45M
0
Common Stock Issued
102.89M
296.61M
5.73M
5.41M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
581k
-5.44M
232k
0
Free Cash Flow
-144.19M
-90.16M
-32.35M
-5.38M
Operating Cash Flow
-139.74M
-81.16M
-29.07M
-4.94M
Capital Expenditures
-4.45M
-8.99M
-3.28M
-442k
Cash at Beginning of Period
406.3M
1.87M
41k
11k
Cash at End of Period
64.95M
406.3M
1.87M
41k
Net Change In Cash
-341.35M
404.43M
1.83M
30k
Retained Earning Schedule
Year
2024
2023
2022
Retained Earnings (Previous Year)
-145.15M
-47M
-6.05M
Net Income
-167.5M
-98.15M
-40.95M
Stock Repurchases
0
0
0
Dividend Paid
0
0
0
Retained Earnings
-312.65M
-145.15M
-47M
Other Distributions
-167.5M
-98.15M
-40.95M
PPE Schedule
Year
2024
2023
2022
Gross PPE
34.78M
38.6M
5.53M
Annual Depreciation
0
3.69M
1.44M
Capital Expenditure
-4.45M
-8.99M
-3.28M
Net PPE
39.22M
43.9M
7.37M
Intangible and Goodwill Schedule
Year
2024
2023
2022
Acquisitions and Adjustments
0
0
0
Goodwill (Previous Year)
0
0
0
Goodwill
0
0
0
All figures are in USD.
